Exogeneous cytosine deaminase gene expression in Bifidobacterium breve I-53-8w for tumor-targeting enzyme/prodrug therapy

Bioscience, Biotechnology and Biochemistry

Volumn 71, Issue 12, 2007, Pages 2921-2926

  Hidaka, Ayumi ^a   Hamaji, Yoshinori ^a   Sasaki, Takayuki ^a   Taniguchi, Shun'ichiro ^b   Fujimori, Minoru ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil (5 FU); Bifidobacterium breve; Cytosine deaminase; Enzyme prodrug therapy; Plasmid

Indexed keywords

BACTERIA; DRUG THERAPY; ENZYME ACTIVITY; GENE EXPRESSION; TUMORS;

ANAEROBIC DOMESTIC BACTERIA; BIFIDOBACTERIUM LONGUM; CYTOSINE DEAMINASE (CD);

NUCLEIC ACIDS;

BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; RATTUS;

ANTINEOPLASTIC AGENT; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; PRODRUG;

ANIMAL; ARTICLE; BIFIDOBACTERIUM; C57BL MOUSE; CANCER TRANSPLANTATION; DRUG DELIVERY SYSTEM; GENETICS; HUMAN; LUNG TUMOR; MALE; METABOLISM; MICROBIOLOGY; MOUSE; PLASMID; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIFIDOBACTERIUM; CELL LINE, TUMOR; CYTOSINE DEAMINASE; DRUG DELIVERY SYSTEMS; FLUCYTOSINE; FLUOROURACIL; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PLASMIDS; PRODRUGS; TRANSPLANTATION, HETEROLOGOUS;

EID: 37649012153     PISSN: 09168451     EISSN: 13476947     Source Type: Journal    
DOI: 10.1271/bbb.70284     Document Type: Article

References (27)

1. Gorbach, S. L., Plaut, A. G., Nahas, L., Weinstein, L., Spanknebel, G., and Levitan, R., Studies of intestinal microflora. II. Microorganisms of the small intestine and their relations to oral and fecal flora. Gastroenterology, 53, 856-867 (1967).
2. Yasui, H., and Ohwaki, M., Enhancement of immune response in Peyer's patch cells cultured with Bifidobacterium breve. J. Dairy Sci., 74, 1187-1195 (1991).
3. Reddy, B. S., and Rivenson, A., Inhibitory effect of Bifidobacterium longum on colon, mammary, and liver carcinogenesis induced by 2-amino-3-methylimidazo-[4,5-f]quinoline, a food mutagen. Cancer Res., 53, 3914-3918 (1993).
4. Pool-Zobel, B. L., Neudecker, C., Domizlaff, I., Ji, S., Schillinger, U., Rumney, C., Moretti, M., Vilarini, I., Scassellati-Sforzolini, R., and Rowland, I., Lactobacillus-and bifidobacterium-mediated antigenotoxicity in the colon of rats. Nutr. Cancer, 26, 365-380 (1996).
5. Saavedra, J. M., Bauman, N. A., Oung, I., Perman, J. A., and Yolken, R. H., Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet, 344, 1046-1049 (1994).
6. Argnani, A., Leer, R., van Luijk, N., and Pouwels, P., A convenient and reproducible method to genetically transform bacteria of the genus Bifidobacterium. Microbiology, 142, 109-114 (1996).
7. Matsumura, H., Takeuchi, A., and Kano, Y., Construction of Escherichia coli-Bifidobacterium longum shuttle vector transforming B. longum 105-A and 108-A. Biosci. Biotechnol. Biochem., 61, 1211-1212 (1997).
8. Nakamura, T., Sasaki, T., Fujimori, M., Yazawa, K., Kano, Y., Amano, J., and Taniguchi, S., Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors. Biosci. Biotechnol. Biochem., 66, 2362-2366 (2002).
9. Yi, C., Huang, Y., Guo, Z. Y., and Wang, S. R., Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma. Acta Pharmacol. Sin., 26, 629-634 (2005).
10. Takata, T., Shirakawa, T., Kawasaki, Y., Kinoshita, S., Gotoh, A., Kano, Y., and Kawabata, M., Genetically engineered Bifidobacterium animalis expressing the Salmonella flagellin gene for the mucosal immunization in a mouse model. J. Gene Med., 8, 1341-1346 (2006).
11. Li, X., Fu, G. F., Fan, Y. R., Liu, W. H., Liu, X. J., Wang, J. J., and Xu, G. X., Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther., 10, 105-111 (2003).
12. Sgorbati, B., Scardovi, V., and Leblanc, D. J., Plasmids in the genus Bifidobacterium. J. Gen. Microbiol., 128, 2121-2131 (1982).
13. Iwata, M., The presence of plasmids in Bifidobacterium breve. Lett. Appl. Microbiol., 9, 165-168 (1989).
14. Lemmon, M. J., van Zijl, P., Fox, M. E., Mauchline, M. L., Giaccia, A. J., Minton, N. P., and Brown, J. M., Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther., 4, 791-796 (1997).
15. Liu, S. C., Minton, N. P., Giaccia, A. J., and Brown, J. M., Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther., 9, 291-296 (2002).
16. Minton, N. P., Clostridia in cancer therapy. Nat. Rev. Microbiol., 1, 237-242 (2003).
17. Theys, J., Barbe, S., Landuyt, W., Nuyts, S., Van Mellaert, L., Wouters, B., Anne, J., and Lambin, P., Tumor-specific gene delivery using genetically engineered bacteria. Curr. Gene Ther., 3, 207-221 (2003).
18. Van Mellaert, L., Barbe, S., and Anne, J., Clostridium spores as anti-tumour agents. Trends Microbiol., 14, 190-196 (2006).
19. King, I., Bermudes, D., Lin, S., Belcourt, M., Pike, J., Troy, K., Le, T., Ittensohn, M., Mao, J., Lang, W., Runyan, J. D., Luo, X., Li, Z., and Zheng, L. M., Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent. Hum. Gene Ther., 13, 1225-1233 (2002).
20. Low, K. B., Ittensohn, M., Le, T., Platt, J., Sodi, S., Amoss, M., Ash, O., Carmichael, E., Chakraborty, A., Fischer, J., Lin, S. L., Luo, X., Miller, S. I., Zheng, L., King, I., Pawelek, J. M., and Bermudes, D., Lipid a mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo. Nat. Biotechnol., 17, 37-41 (1999).
21. Pawelek, J. M., Low, K. B., and Bermudes, D., Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res., 57, 4537-4544 (1997).
22. Zhao, M., Yang, M., Ma, H., Li, X., Tan, X., Li, S., Yang, Z., and Hoffman, R. M., Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res., 66, 7647-7652 (2006).
23. Yazawa, K., Fujimori, M., Amano, J., Kano, Y., and Taniguchi, S., Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors. Cancer Gene Ther., 7, 269-274 (2000).
24. Yazawa, K., Fujimori, M., Nakamura, T., Sasaki, T., Amano, J., Kano, Y., and Taniguchi, S., Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res. Treat., 66, 165-170 (2001).
25. Sasaki, T., Fujimori, M., Hamaji, Y., Hama, Y., Ito, K., Amano, J., and Taniguchi, S., Genetically engineered Bifidobacterium longum for tumor-targeting enzyme-prodrug therapy of autochthonous mammary tumors in rats. Cancer Sci., 97, 649-657 (2006).
26. Hamaji, Y., Fujimori, M., Sasaki, T., Matsuhashi, H., Matsui-Seki, K., Shimatani-Shibata, Y., Kano, Y., Amano, J., and Taniguchi, S., Strong enhancement of recombinant cytosine deaminase activity in Bifidobacterium longum for tumor-targeting enzyme/prodrug therapy. Biosci. Biotechnol. Biochem., 71, 874-883 (2007).
27. Rossi, M., Brigidi, P., and Matteuzzi, D., An efficient transformation system for Bifidobacterium spp. Lett. Appl. Microbiol., 24, 33-36 (1997).